Glutathione Found to Fight Ferroptosis Through a Newly Discovered Pathway
A Cell study reveals glutathione suppresses ferroptosis independently of GPX4, acting through FSP1 to generate lipid-protecting reduced ubiquinone.
Summary
Scientists have long known that glutathione (GSH) — the body's master antioxidant — protects cells from ferroptosis, a form of iron-driven cell death, primarily by fueling the enzyme GPX4. A new study published in Cell overturns this assumption by showing GSH can protect cells even when GPX4 is completely knocked out. Using genome-wide CRISPR screening, researchers identified FSP1 as the key mediator of this alternative pathway. FSP1 uses GSH to generate reduced ubiquinone (CoQ10 in its active form), which then neutralizes toxic oxidized lipids. This mechanism operates without the cofactor FAD, distinguishing it from the previously known NAD(P)H-driven FSP1 pathway. The discovery means GSH metabolism plays a broader anti-ferroptosis role than recognized, with implications for cancer therapy, neurodegeneration, and other ferroptosis-related diseases.
Detailed Summary
Ferroptosis — a form of regulated cell death driven by the accumulation of oxidized lipids — has emerged as a central mechanism in aging, neurodegeneration, organ injury, and cancer. Blocking or promoting ferroptosis, depending on context, is a major therapeutic goal. The dominant dogma held that glutathione (GSH) suppresses ferroptosis almost exclusively by serving as a cofactor for glutathione peroxidase 4 (GPX4), which neutralizes toxic lipid peroxides. This new Cell paper challenges that framework with a surprising discovery.
Researchers at Shandong University and collaborating institutions observed that GSH continued to robustly protect multiple cell types from ferroptosis even after GPX4 was genetically deleted. This finding implied an entirely separate GSH-dependent protective mechanism. To identify it, they conducted genome-wide CRISPR-Cas9 screening — a powerful unbiased approach — and pinpointed ferroptosis suppressor protein 1 (FSP1) as the essential mediator.
Mechanistically, FSP1 was found to use GSH to generate reduced ubiquinone (CoQ10H2), which scavenges oxidized lipids and halts ferroptotic cell death. This differs fundamentally from FSP1's known mechanism, in which it uses NAD(P)H and the cofactor FAD to reduce ubiquinone. The new GSH-driven reduction is FAD-independent — a biochemically distinct reaction, suggesting FSP1 is a more versatile anti-ferroptosis enzyme than previously appreciated. Inhibiting FSP1 abolished GSH's protective effect both in cell culture and in animal models.
For longevity science, ferroptosis is increasingly linked to age-related degeneration in the brain, heart, and muscle. Strategies that boost GSH — including NAC supplementation, whey protein, and glycine — may confer broader ferroptosis protection than previously credited. In oncology, cancer cells that evade GPX4-targeted therapies may remain vulnerable to combined GSH-FSP1 inhibition.
Caveats: this summary is based on the abstract only; full mechanistic detail and in vivo model specifics are unavailable without access to the complete paper.
Key Findings
- GSH suppresses ferroptosis even without GPX4, disproving the assumption that GPX4 is GSH's sole ferroptosis-protective target.
- Genome-wide CRISPR screening identified FSP1 as the key mediator of GPX4-independent, GSH-driven ferroptosis suppression.
- FSP1 uses GSH to generate reduced ubiquinone (CoQ10H2), which scavenges toxic oxidized lipids to block cell death.
- This new FSP1-GSH pathway is FAD-independent, making it biochemically distinct from the previously known NAD(P)H-FSP1 mechanism.
- Inhibiting FSP1 eliminated GSH's protective effect in both cell and animal models, validating FSP1 as a therapeutic target.
Methodology
The study used GPX4 knockout cell lines across multiple cell types to establish GPX4-independent ferroptosis protection by GSH. Genome-wide CRISPR-Cas9 loss-of-function screening was employed to identify the responsible factor. In vitro findings were validated in vivo, though specific animal models are not described in the abstract.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; mechanistic depth, specific in vivo models, and quantitative effect sizes cannot be assessed. The clinical translation of FSP1-GSH pathway findings to human aging or disease remains to be established. It is unclear whether the FAD-independent mechanism operates under physiological GSH concentrations or only under supplemented conditions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: